UNIQURE NV

UNIQURE NV’s CEO executes a rule‑10b5‑1 plan, buying low at €31.71 and selling high at €50.02, showing confidence in the gene‑therapy pipeline and stable governance.

Kapusta Matthew C’s June 2026 Rule 10b‑5‑1 trades: 62,581 shares bought at €19.39 and 200k sold between €42‑48.65, showing confidence and liquidity strategy in UNIQURE’s booming gene‑therapy stock.

Insider Madhavan’s June 17 buy of 10 295 UNIQURE NV shares signals confidence ahead of positive AMT‑260 data, suggesting a potential rally for gene‑therapy investors.

Insightful UNIQURE NV insider activity shows routine incentive exercises, balanced buys/sells, and no hidden bearish signals for long‑term investors.

Insider buying: Kaye Jack buys 2,645 UNIQURE shares at €16, signals confidence in gene‑therapy pipeline despite volatility and mixed sales.

UniQure insiders buy big, signaling confidence in future gene‑therapy upside – but investors should weigh high volatility, FDA risk, and dilution concerns.

Insider buys at uniQure show senior execs backing its gene‑therapy pipeline—yet the stock faces analyst downgrades and a lawsuit, leaving investors weighing long‑term confidence against short‑term volatility.

CEO Matthew Kapusta’s March 2026 sale of 34,437 shares at $9.95 reflects routine tax‑covering, not a confidence loss – insiders remain long‑term holders while the market watches UniQure’s regulatory milestones and investor sentiment.

CEO insider sell‑off sparks debate on UniQure’s gene‑therapy outlook, raising questions about management confidence amid strong market gains.

Insider trades at uniQure reveal a cautious bullish stance: director Robert buys deep‑value shares, sells near‑peak prices, signaling confidence in upcoming gene‑therapy breakthroughs and potential rally.